Report Content
Chapter 1 Methodology & Scope
1.1 Market definition & scope
1.2 Base estimates & calculations
1.2.1 Data collection
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Global ophthalmology contract research organization (CRO) industry 3600 synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Service type trends
2.1.4 Therapy trends
2.1.5 End-use trends
Chapter 3 Ophthalmology Contract Research Organization (CRO) Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2018 - 2032 (USD Million)
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Rising prevalence of eye disorders
3.3.1.2 Increasing outsourcing for ophthalmology R&D activities
3.3.1.3 Increasing demand for novel ophthalmic therapies
3.3.2 Industry pitfalls & challenges
3.3.2.1 Varying regulatory requirements across regions
3.4 Growth potential analysis
3.4.1 By service type
3.4.2 By therapy
3.4.3 By end-use
3.5 COVID-19 impact analysis
3.6 Ophthalmology clinical trial analysis
3.6.1 Ophthalmology clinical trial volume, by region, 2018 - 2022
3.6.2 Ophthalmology clinical trial volume, by indication, 2018 - 2022
3.6.3 Ophthalmology clinical trial volume, by phase of development, 2018 - 2022
3.7 Regulatory landscape
3.7.1 U.S.
3.7.2 Europe
3.8 Drug discovery and development process
3.9 Porter's analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company positioning matrix
4.4 Strategy dashboard, 2022
Chapter 5 Ophthalmology Contract Research Organization (CRO) Market, By Service Type, 2018 - 2032 (USD Million)
5.1 Key trends, by service type
5.2 Early phase development services
5.3 Clinical research
5.3.1 Phase I
5.3.2 Phase II
5.3.3 Phase III
5.3.4 Phase IV
5.4 Laboratory services
5.5 Regulatory consulting services
Chapter 6 Ophthalmology Contract Research Organization (CRO) Market, By Therapy, 2018 – 2032 (USD Million)
6.1 Key trends, by therapy
6.2 Traditional interventions
6.2.1 Anti-inflammatory interventions
6.2.1.1 Corticosteroids
6.2.1.2 NSAIDs
6.2.1.3 Immunomodulators
6.2.1.4 Other anti-inflammatory interventions
6.2.2 Anti-oxidative interventions
6.2.3 Other traditional interventions
6.3 Advanced interventions
6.3.1 Cell therapy
6.3.2 Gene theray
6.3.3 Other advanced interventions
Chapter 7 Ophthalmology Contract Research Organization (CRO) Market, By End-user, 2018 – 2032 (USD Million)
7.1 Key trends, by end-user
7.2 Pharma/biopharma companies
7.3 Medical device companies
7.4 Academic institutes
Chapter 8 Ophthalmology Contract Research Organization (CRO) Market, By Region, 2018 – 2032 (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 MEA
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of MEA
Chapter 9 Company Profiles
9.1 Charles River Laboratories International, Inc.
9.2 ICON plc
9.3 Laboratory Corporation of America Holdings (Covance Inc.)
9.4 Medpace, Inc.
9.5 Pharmaceutical Product Development (Thermo Fisher Scientific, Inc.)
9.6 Syneos Health
9.7 Worldwide Clinical Trials
9.8 WuXi AppTec
9.9 ORA Inc.
9.10 CTRG (Clinical Trial Resource Group)
9.11 Iris Pharma
9.12 Trial Runners
9.13 The Emmes Company, LLC
9.14 Lexitas Pharma Services, Inc.
9.15 ProTrial Research, Inc.
9.16 TFS HealthScience
